Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Decitabine. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel preparation method of Decitabine using 1-methyl-2-deoxy-D-ribose improves yield and reduces purification costs for pharmaceutical intermediates.
Patent CN111471077B reveals a novel 2-deoxy-D-ribose derivative route achieving 8:1 beta-selectivity. Discover cost-effective, scalable manufacturing for oncology APIs.
Advanced decitabine synthesis patent analysis reveals improved purity and yield for pharmaceutical intermediate supply chains reducing costs.
Patent CN112142804B reveals a novel decitabine preparation method using supercritical fluid separation, offering high purity and reduced solvent consumption for pharmaceutical manufacturing.
Patent CN111377989B reveals a high-selectivity synthesis for decitabine intermediates, offering superior beta-isomer ratios and scalable purification for cost-effective API manufacturing.
Novel silanization route for Decitabine intermediates offering high purity and industrial scalability without column chromatography.
Novel stepwise deprotection method for Decitabine ensures high optical purity and scalable industrial production for pharmaceutical intermediates supply chain efficiency.
Patent CN101821278A reveals improved decitabine synthesis. Enhanced isomer ratio and yield offer supply chain stability for pharmaceutical intermediates.
Patent CN109503689B reveals a novel Guadecitabine synthesis route eliminating toxic reagents. Discover cost reduction strategies and scalable manufacturing insights for pharmaceutical intermediates.
Patent CN101712708A reveals a scalable Decitabine synthesis using pivaloyl protection, eliminating chromatography for significant cost reduction and high purity.
Patent CN106046089A reveals a cobalt-catalyzed route for Decitabine. Achieves high beta-selectivity and purity for reliable pharmaceutical intermediate supply chains.
Advanced preparation method for Decitabine achieving 99.8% purity via novel protecting group strategy. Ideal for pharmaceutical intermediate manufacturing and cost reduction.
Patent CN101497639B details a scalable Decitabine synthesis using toluoyl protection and fractional crystallization, offering significant cost reduction in pharmaceutical manufacturing.
Patent CN108239128A reveals TMSOTf catalysis for high-purity beta-nucleosides. Enhances supply chain reliability and cost reduction in pharma manufacturing.
Patent CN111377982B details a novel solid acid catalyzed glycosylation for decitabine intermediates, offering high beta-selectivity and simplified purification for pharmaceutical manufacturing.
Novel patent CN102010455A details a high-purity Decitabine route avoiding isomer separation. Ideal for cost reduction in API intermediate manufacturing.
Patent CN102010455B reveals a novel Decitabine synthesis avoiding isomer separation. High purity >99.85% via Barton-McCombie deoxygenation for cost-effective manufacturing.
Patent CN111377986B details a novel purification method for decitabine intermediate II, removing critical impurities to enhance beta-configuration yield and supply reliability.